MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.690
-0.100
-3.58%
Closed 16:00 04/01 EDT
OPEN
2.720
PREV CLOSE
2.790
HIGH
2.840
LOW
2.610
VOLUME
10.94K
TURNOVER
--
52 WEEK HIGH
20.45
52 WEEK LOW
2.210
MARKET CAP
4.29M
P/E (TTM)
-0.5950
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.

EPS

ABIO News

More
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52
  • The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
  • Benzinga · 02/28 12:28
  • WLL, SPEX, CODX and AIM among midday movers
  • Seeking Alpha - Article · 02/27 18:00
  • The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
  • Benzinga · 02/21 12:46

Industry

Pharmaceuticals
-2.46%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About ABIO

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.